Deltex Medical Group plc
Deltex Medical Group plc (DEMG.L) Stock Overview
Explore Deltex Medical Group plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
663.6K
P/E Ratio
-0.35
EPS (TTM)
N/A
ROE
-0.42%
DEMG.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Deltex Medical Group plc (DEMG.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.03.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.35 and a market capitalization of 663.6K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient's central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting. Its products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.
Andrew Jonathan Mears
24
Terminus Road, Chichester
2001